NASDAQ: DAWNDay One Biopharmaceuticals Inc Stock
$14.85+0.24 (+1.64%)
Updated Apr 17, 2024
DAWN Price
$14.85
Fair Value Price
$2.89
Market Cap
$1.30B
52 Week Low
$9.67
52 Week High
$17.85
P/E
-6.27x
P/B
3.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$188.92M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$147M
Beta
0.62
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DAWN Overview
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with genetically defined cancers. Its lead product candidates are DAY101 and Pimasertib. Day One Biopharmaceuticals was incorporated in 2018 and is headquartered in South San Francisco, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DAWN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DAWN ($14.85) is overvalued by 414.22% relative to our estimate of its Fair Value price of $2.89 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DAWN ($14.85) is not significantly undervalued (414.22%) relative to our estimate of its Fair Value price of $2.89 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DAWN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DAWN due diligence checks available for Premium users.
Be the first to know about important DAWN news, forecast changes, insider trades & much more!
DAWN News
Valuation
DAWN fair value
Fair Value of DAWN stock based on Discounted Cash Flow (DCF)
Price
$14.85
Fair Value
$2.89
Overvalued by
414.22%
DAWN ($14.85) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DAWN ($14.85) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DAWN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DAWN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.27x
Industry
15.83x
Market
41.64x
DAWN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.74x
Industry
5.83x
DAWN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DAWN's financial health
Profit margin
Revenue
$0.0
Net Income
-$54.5M
Profit Margin
0%
DAWN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$376.0M
Liabilities
$29.5M
Debt to equity
0.09
DAWN's short-term assets ($375.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DAWN's short-term assets ($375.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DAWN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$41.4M
Investing
$30.4M
Financing
$597.0k
DAWN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DAWN vs Biotech Stocks
Day One Biopharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.